Two's a Crowd: Versartis Raises $21 Million Series B, Cleaves Off Diabetes Asset to Form Diartis Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Citing different financial needs, Versartis' backers have created Diartis to take its GLP-1 molecule to proof of concept, while Versartis focuses on human growth hormone.
You may also be interested in...
Financings of the Fortnight Wants To Spin You Right 'Round, And Out
Recently public Akebia is just one of the many biotechs making a case for spin-outs driven by economic needs. Also, Sangamo, Ataxion, Galmed and SAGE tap the financing pool.
After Complex Sale, Amira Scientist And VC Team Up Again For Discovery Start-up
Versant Ventures is backing Inception Sciences, a new company led by former Amira chief scientist Peppi Prasit that aims to spin out multiple programs into separate companies, a new model gaining traction in the biotech world.
After Complex Sale, Amira Scientist And VC Team Up Again For Discovery Start-up
Versant Ventures is backing Inception Sciences, a new company led by former Amira chief scientist Peppi Prasit that aims to spin out multiple programs into separate companies, a new model gaining traction in the biotech world.